EU authorizes Eisai-Biogen's drug for early Alzheimer's treatment
This makes Leqembi the first approved drug in the European Union that targets an underlying cause of the fatal mind-wasting disease. It had been under regulatory review since January 2023.
here.
Biogen's head of development, Priya Singhal, said the company and its partner Eisai were "moving with urgency" to make the therapy available to patients in Europe.
Rival Eli Lilly's (LLY.N), opens new tab Alzheimer's drug was rejected last month as its benefits were not significant enough to outweigh serious safety risks.
The authorization allows the use of Leqembi to treat people with only one or no copy of the ApoE4 gene and who exhibit sticky clumps of a protein called amyloid beta in the brain, which is believed to be a hallmark of Alzheimer's.
The decision to exclude those with two copies of the gene is the regulator leaning on the side of safety, said William Blair analyst Myles Minter. He estimates over $900 million peak sales for the drug in the 2030s.
The EC's decision is in line with that of the European Medicines Agency, which recently reiterated that Leqembi would be approved for a narrower set of patients than those in which it was tested.
The regulator had backed Leqembi for patients with only one copy of the ApoE4 gene, but the EC had requested another safety review. Initially, the European medicines regulator had refused to back the drug's approval due to serious safety risks.
Leqembi is approved in the United States for patients with two copies of the gene, but patients must undergo regular brain scans to monitor for any brain swelling.
Leqembi is also approved in Japan, China, Great Britain and several other markets.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
an hour ago
- Reuters
Organ donation groups sue to block new US certification system
Aug 4 (Reuters) - A group of non-profits that procure organs for transplant is suing to block the U.S. Department of Health and Human Services from using a new method to evaluate their work, saying it violates federal law and will likely cause many providers to lose their certification. The lawsuit, filed Friday in federal court in Tampa, Florida, said the new certification process, set to begin next year, unfairly ranks providers by the number of donations and transplants they complete, using the same scale to assess organizations covering vastly different geographic areas and populations. The plaintiffs asked the court to bar the new process before it begins, arguing it was not properly implemented under the Administrative Procedure Act and runs afoul of Congress' directive in the 1984 National Organ Transplant Act to use multiple measures to evaluate providers. The legal challenge comes as HHS has announced increased scrutiny of organ procurement organizations and threatened to close a major provider after an HHS probe identified cases where doctors had begun to retrieve organs while patients still showed signs of life. The organizations that filed the lawsuit, including LifeLink Foundation and OneLegacy, said they will be seeking recertification next year to retrieve donated organs in states including Texas, Florida and Georgia. The plaintiffs in a statement said they are suing to require the agency "to comply with its statutory obligations, which is necessary to protect patients' access to lifesaving transplants and ensure the stability of our nation's organ donation and transplant system." An HHS spokesperson declined to comment on the lawsuit but said the agency "remains committed to holding organ procurement organizations accountable and restoring integrity and transparency to organ donation and transplant policy, always putting patients first." HHS adopted the new evaluation process in a 2020 regulation. The lawsuit said it will rank organizations based on the number of donations and transplants they completed in the last 12 months and would decertify the lowest-ranked providers. The rule was introduced as part of HHS' effort to implement an executive order on kidney donations issued during President Donald Trump's first term. The agency said the change was meant to increase transparency and competition in the organ transplant system. HHS announced last month it was undertaking a series of reforms for the organ transplant system, following a New York Times report and an investigation by the agency's Health Resources and Services Administration. The probe examined 351 cases where organ donation was authorized but not completed. It found 73 patients had shown neurological signs incompatible with organ donation and at least 28 patients may not have been deceased at the time the organ retrieval process began. The lawsuit is LifeLink Foundation v. Kennedy, U.S. District Court for the Middle District of Florida, No. 8:25-cv-02042. For the plaintiffs: Val Leppert, Mark Polston, Ashley Parrish, Adam Robison and Christie Cardon of King & Spalding; and Brigid Merenda and Richard Hanchett of Trenam, Kemker, Scharf, Barkin, Frye, O'Neill and Mullis For HHS: Not yet available
Reuters
13 hours ago
- Reuters
July quake appears to have damaged Russian nuclear sub base, NY Times reports
Aug 4 (Reuters) - A nuclear submarine base in Russia's remote Far East region was damaged last week following one of the most powerful earthquakes to hit the area in decades, the New York Times reported on Monday, citing satellite images. Photos captured by Planet Labs, a commercial satellite imaging firm, show damage to a floating pier at the Rybachiy submarine base on the Kamchatka Peninsula, the newspaper reported. One section of the pier appears to have broken away from its anchor point. Aside from the damaged pier, the satellite imagery does not show any other major destruction. Reuters could not independently verify the report. There was no immediate response from Russia's defence ministry outside business hours to a Reuters request for comment. A very powerful magnitude 8.8 earthquake off Russia's Far Eastern Kamchatka coast on Wednesday triggered tsunami warnings as far away as French Polynesia and Chile, and was followed by an eruption of the most active volcano on the peninsula. The Rybachiy nuclear submarine base, a strategic hub for Russia's Pacific Fleet, serves as a facility for the maintenance, deployment, and operations of the country's nuclear-powered submarines in the Pacific region.
Reuters
15 hours ago
- Reuters
Hims and Hers beats quarterly profit on steady subscription growth
NEW YORK, Aug 4 (Reuters) - Hims and Hers Health (HIMS.N), opens new tab beat Wall Street estimates for second-quarter profit on Monday, aided by continued subscription growth and surging volume in the telehealth company's weight-loss business. The company reported a quarterly profit of 17 cents per share, higher than the average analyst estimate of 15 cents, according to LSEG data. However, shares fell about 10% in extended trading as quarterly revenue of $544.8 million missed analysts' average expectation of $551.6 million.
